I am sorry you feel that way. I quoted you to try to give a fair representation of your piece. The original title and message of your piece as posted yesterday was this 1/
You made an unacknowledged change to that title today to include public health, which I am glad you did. I think it improves the piece 2/
But I don’t feel your inclusion of this short paragraph in your piece about how we were losing the war against microbes until the vaccines accurately conveys the reality:
progress against infectious diseases in many nations occurred *ahead* of development of most vaccines 3/
In other words, I don’t agree with that excerpted paragraph says the same thing as my thread 4/
All that said, I did not write this thread to try to embarrass you. As I stated to open the thread, I am a fan of your work and the site. I meant it. 5/
I only wrote the thread because there are many policymakers in US and perhaps other nations too that are indeed acting right now as that there is nothing we can do against #COVID19 but wait for a vaccine.
That is just not so 6/
In current situation, I feared that people may take wrong message from your post, even if it may well not have been your intention that they do so 7/
The thread was meant as a substantive, constructive criticism of the accuracy of public post on widely read site and how it might be misused.
Not a meant as personal attack. 8/8
• • •
Missing some Tweet in this thread? You can try to
force a refresh
The US has most outstanding, but that is misleading as President Biden just this week added 500m to US total pledged donation by 1.1B COVID vaccine doses
Maximizing potential benefit of vaccine donations depends on doses going where they can do the"most good" but there's no consensus on where that would be
This week's summit in Cornwall, UK should be the time when G7 leaders finally act on their promises to send surplus COVID-19 vaccine supplies to the many other countries where they remain scarce #G7UK
COVAX has been criticized by @ZekeEmanuel@GovindPersad & others for its population-based allocation scheme that does not direct most of its early vaccine supplies to the settings at the greatest risk of otherwise having high COVID-19 death rates 3/ nytimes.com/2021/05/24/opi…
Results published in Lancet indicate say this a/b 1 dose regimen
It will be interesting to see public response and distribution strategy for regimen w/lower efficacy than Pfizer/Moderna options & uncertainty about duration of protection thelancet.com/journals/lance…
Apparently, Oxford/AstraZeneca has not even filed a submission package with EMA yet. FDA decision isn't coming soon either.
This is such an important vaccine for global access and so much is strange about how its sponsors have pursued it reuters.com/article/us-hea…